Redox Biology,
Год журнала:
2024,
Номер
69, С. 103027 - 103027
Опубликована: Янв. 3, 2024
Non-alcoholic
steatohepatitis
(NASH)
is
a
common
chronic
liver
disease
that
compromises
function,
for
which
there
not
specifically
approved
medicine.
Recent
research
has
identified
transcription
factor
NRF2
as
potential
therapeutic
target.
However,
current
activators,
designed
to
inhibit
its
repressor
KEAP1,
exhibit
unwanted
side
effects.
Alternatively,
we
previously
introduced
PHAR,
protein-protein
interaction
inhibitor
of
NRF2/β-TrCP,
induces
mild
activation
and
selectively
activates
in
the
liver,
close
normal
physiological
levels.
Herein,
assessed
effect
PHAR
protection
against
NASH
progression
fibrosis.
We
conducted
experiments
demonstrate
effectively
activated
hepatocytes,
Kupffer
cells,
stellate
cells.
Then,
used
STAM
mouse
model
NASH,
based
on
partial
damage
endocrine
pancreas
insulin
secretion
impairment,
followed
by
high
fat
diet.
Non-invasive
analysis
using
MRI
revealed
protects
accumulation.
Moreover,
attenuated
key
markers
progression,
including
steatosis,
hepatocellular
ballooning,
inflammation,
Notably,
transcriptomic
data
indicate
led
upregulation
3
anti-fibrotic
genes
(Plg,
Serpina1a,
Bmp7)
downregulation
6
pro-fibrotic
(including
Acta2
Col3a1),
11
extracellular
matrix
remodeling,
8
inflammatory
genes.
Overall,
our
study
suggests
via
holds
promise
strategy
addressing
New England Journal of Medicine,
Год журнала:
2023,
Номер
389(11), С. 998 - 1008
Опубликована: Июнь 24, 2023
Pegozafermin
is
a
long-acting
glycopegylated
(pegylated
with
the
use
of
site-specific
glycosyltransferases)
fibroblast
growth
factor
21
(FGF21)
analogue
in
development
for
treatment
nonalcoholic
steatohepatitis
(NASH)
and
severe
hypertriglyceridemia.
The
efficacy
safety
pegozafermin
patients
biopsy-proven
noncirrhotic
NASH
are
not
well
established.
Signal Transduction and Targeted Therapy,
Год журнала:
2024,
Номер
9(1)
Опубликована: Сен. 18, 2024
The
glucagon-like
peptide-1
(GLP-1)
receptor,
known
as
GLP-1R,
is
a
vital
component
of
the
G
protein-coupled
receptor
(GPCR)
family
and
found
primarily
on
surfaces
various
cell
types
within
human
body.
This
specifically
interacts
with
GLP-1,
key
hormone
that
plays
an
integral
role
in
regulating
blood
glucose
levels,
lipid
metabolism,
several
other
crucial
biological
functions.
In
recent
years,
GLP-1
medications
have
become
focal
point
medical
community
due
to
their
innovative
treatment
mechanisms,
significant
therapeutic
efficacy,
broad
development
prospects.
article
thoroughly
traces
developmental
milestones
drugs,
from
initial
discovery
clinical
application,
detailing
evolution
diverse
along
distinct
pharmacological
properties.
Additionally,
this
paper
explores
potential
applications
agonists
(GLP-1RAs)
fields
such
neuroprotection,
anti-infection
measures,
reduction
inflammation,
enhancement
cardiovascular
function.
It
provides
in-depth
assessment
effectiveness
GLP-1RAs
across
multiple
body
systems-including
nervous,
cardiovascular,
musculoskeletal,
digestive
systems.
includes
integrating
latest
trial
data
delving
into
signaling
pathways
mechanisms.
primary
goal
emphasize
extensive
benefits
using
treating
spectrum
diseases,
obesity,
non-alcoholic
fatty
liver
disease
(NAFLD),
neurodegenerative
musculoskeletal
forms
cancer.
ongoing
new
indications
for
drugs
offers
promising
prospects
further
expanding
interventions,
showcasing
field.
International Journal of Molecular Sciences,
Год журнала:
2023,
Номер
24(3), С. 2844 - 2844
Опубликована: Фев. 2, 2023
Non-alcoholic
fatty
liver
disease
(NAFLD)
is
the
most
prevalent
chronic
that
affects
approximately
one-quarter
of
global
adult
population,
posing
a
significant
threat
to
human
health
with
wide-ranging
social
and
economic
implications.
The
main
characteristic
NAFLD
considered
excessive
fat
accumulated
deposited
in
hepatocytes
without
excess
alcohol
intake
or
some
other
pathological
causes.
progressive
disease,
ranging
from
steatosis
non-alcoholic
steatohepatitis
(NASH),
cirrhosis,
hepatocellular
carcinoma,
transplantation,
death.
Therefore,
will
probably
emerge
as
leading
cause
end-stage
coming
decades.
Unlike
highly
diseases,
has
received
little
attention
public
community.
Liver
biopsy
currently
gold
standard
for
diagnosis
staging
because
absence
noninvasive
specific
biomarkers.
Due
complex
pathophysiological
mechanisms
heterogeneity
phenotype,
no
pharmacological
therapies
have
been
approved
at
present,
although
several
drugs
are
advanced
stages
development.
This
review
summarizes
current
evidence
on
pathogenesis,
treatment
NAFLD.
Frontiers in Cell and Developmental Biology,
Год журнала:
2024,
Номер
12
Опубликована: Июль 16, 2024
Metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD),
previously
known
as
non-alcoholic
fatty
(NAFLD),
is
the
most
common
disorder
worldwide,
with
an
estimated
global
prevalence
of
more
than
31%.
steatohepatitis
(MASH),
formerly
(NASH),
a
progressive
form
MASLD
characterized
by
hepatic
steatosis,
inflammation,
and
fibrosis.
This
review
aims
to
provide
comprehensive
analysis
extrahepatic
manifestations
MASH,
focusing
on
chronic
diseases
related
cardiovascular,
muscular,
renal
systems.
A
systematic
published
studies
literature
was
conducted
summarize
findings
systemic
impacts
MASH.
The
focused
association
MASH
metabolic
comorbidities,
cardiovascular
mortality,
sarcopenia,
kidney
disease.
Mechanistic
insights
into
concept
lipotoxic
inflammatory
"spill
over"
from
MASH-affected
were
also
explored.
are
highly
associated
(50%-80%)
other
comorbidities
such
impaired
insulin
response,
type
2
diabetes,
dyslipidemia,
hypertriglyceridemia,
hypertension.
Furthermore,
90%
obese
patients
diabetes
have
Data
suggest
that
in
middle-aged
individuals
(especially
those
aged
45-54),
independent
risk
factor
for
plays
crucial
role
mediating
pathological
effects
observed.
Understanding
multifaceted
impact
heart,
muscle,
early
detection
stratification.
knowledge
timely
implementing
management
strategies
addressing
multi-organ
involvement
pathogenesis.
Biomedicines,
Год журнала:
2024,
Номер
12(2), С. 397 - 397
Опубликована: Фев. 8, 2024
Non-alcoholic
fatty
liver
disease
(NAFLD)
is
a
widespread
contributor
to
chronic
globally.
A
recent
consensus
on
renaming
was
established,
and
metabolic
dysfunction-associated
steatotic
disease,
MASLD,
chosen
as
the
replacement
for
NAFLD.
The
disease’s
range
extends
from
less
severe
previously
known
non-alcoholic
(NAFL),
more
intense
steatohepatitis
(MASH),
(NASH),
characterized
by
inflammation
apoptosis.
This
research
project
endeavors
comprehensively
synthesize
most
studies
encompassing
wide
spectrum
of
topics
such
pathophysiology,
risk
factors,
dietary
influences,
lifestyle
management,
genetics,
epigenetics,
therapeutic
approaches,
prospective
trajectory
particularly
exploring
its
connection
with
organoids.
Alimentary Pharmacology & Therapeutics,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 2, 2025
The
laxative
lubiprostone
has
been
shown
to
decrease
intestinal
permeability.
We
aimed
assess
the
safety
and
efficacy
of
administered
for
48
weeks
in
patients
with
metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD).
